SLC5A2 and diabetes mellitus: SGLT2 is a cotransporter which reabsorbs glucose in the tubular nephron; by inhibiting SGLT2, glucose reabsorption is reduced and is instead excreted in the urine.11,12 Despite some evidence indicating direct cardiac effects of SGLT2 inhibitors,13 it is likely that they have many indirect effects, such as via altered circulating concentrations of fatty acids and ketones.14 Hence, even our understanding of existing therapeutics is limited, further highlighting the need to understand how DM affects the heart and its constituent cells at a molecular level.